Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

"Offering Zepbound single-dose vials […] through another platform to LillyDirect will help ensure broader availability of ...

Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name Zepbound (though doctors have also prescribed Mounjaro for patients ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that its weight loss treatment, Zepbound (tirzepatide), outperformed Novo ...

Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival Novo Nordisk’s NVO Wegovy (semaglutide) in a weight-loss head-to ...

Zepbound (tirzepatide) is a prescription drug that’s used for weight loss in certain adults. Zepbound comes as a liquid solution inside prefilled injection pens. You’ll inject the drug under ...

How to get Zepbound Noom Med requires a healthcare professional appointment and lab tests before prescribing Zepbound. It will connect people to a healthcare professional, who will review their ...

Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the country's National Institute for Health and Care Excellence ("NICE") said ...

In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk's Wegovy. People taking Zepbound lost 20.2% of ...

Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than rival Novo Nordisk’s NVO Wegovy in a first-ever head-to-head obesity ...

(CNN) — Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. (CNN) — Adults taking Zepbound lost 47% more ...

That's according to new data from drug savings company GoodRx, which examined fill trends and spending patterns for weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.